Clinical Trials Logo
  1. Home
  2. Neoplasms
  3. NCT05440240
  4. Details
NCT05440240 Clinical Trial

Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture

Neoplasms Clinical Trial

Official title:
Percutaneous Needle Fasciotomy (PNF) +/- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05440240
Other study ID # 2022-985
Secondary ID 2022-501021-20-0
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 10, 2023
Est. completion date March 2030

Study information
Verified date May 2023
Source Regionshospitalet Silkeborg
Contact Laura H Matthiesen, MS, PhD-student
Phone 004561281917
Email lather@rm.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparing percutaneous needle fasciotomy +/- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.

Recruitment information / eligibility
Status Recruiting
Enrollment 400
Est. completion date March 2030
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 45 Years to 99 Years
Eligibility Sufficient correction of metacarpophalangeal (MCP) joint during the PNF treatment, defined as <20° passive extension deficit (PED), is a prerequisite for inclusion. Inclusion Criteria: - Dupuytren contracture (DC) of = 20° PED in MCP joint measured with a goniometer - DC of either II-V finger - Well-defined/palpable cord Exclusion Criteria: - Legally incapacitated - Previous study inclusion with another finger ray - Isolated proximal interphalangeal (PIP) or distal interphalangeal (DIP) joint contracture, defined as MCP joint contracture < 20° PED regardless of the deficit in the PIP or DIP joint - Previous hand surgery of the affected finger for any reason - Known allergy to the study medication - Anticoagulant therapy (Acetylsalicylic acid is NOT an exclusion criterion) - Pregnant or lactation - Insulin dependent diabetes mellitus - Ongoing systemic infection or local infection at the site of the procedure - Rheumatoid arthritis - Amyloidosis or mucopolysaccharidosis - Unable to communicate, cooperate or participate in follow-up

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Percutaneous needle fasciotomy
Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
Drug:
• Corticosteroid injection
Depo-Medrol
Other:
• Saline injection
Isotonic saline

Locations
Country Name City State
Denmark Silkeborg Regional Hospital Silkeborg

Sponsors (1)
Lead Sponsor Collaborator
Regionshospitalet Silkeborg

Country where clinical trial is conducted

Denmark, 

Outcome
Type Measure Description Time frame Safety issue
Primary Recurrence rate Recurrence is defined as 20 degrees or more passive extension deficit in metacarpophalangeal joint from baseline 2 years
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT03190811 - Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors Phase 1/Phase 2